- - - - - - -
You are about to be redirected to a site intended for people with primary HLH or their caregivers.
You are being redirected to a third party website.
Sobi takes no responsibility for the content of this website.
Please fill out and submit the form below and a Sobi Health Systems Director (HSD) will reach out to you.
If you have a reimbursement question, click here.
Primary hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory condition that mostly affects children, but can also occur in adults and teenagers.1-4
Gamifant reduces the inflammatory symptoms of primary HLH by neutralizing IFNγ.5
Gamifant is given as an intravenous infusion twice per week until the patient no longer requires therapy for the treatment of HLH or until hematopoietic stem cell transplantation (HSCT) is performed.5
Contact your Sobi Health Systems Director to understand Gamifant ordering options. Connect with your Reimbursement Manager for your individual patient's insurance coverage policy and reimbursement pathway.